Historical record - last NADAC effective date: 7/1/2024
Product Information
LICART 1.3% PATCH is a brand product labeled by IBSA Pharma Inc., priced at $24.7113 per EA under NDC 71858030505. Its NADAC has been published 68 times since Jun 21, 2023.
FDA first approved this application on Dec 19, 2018.
Strength
.013 g/1
Manufacturer
IBSA Pharma Inc.NDC
71858030505
Classification
Brand
Dosage Form
SYSTEM
Route
TOPICAL
Effective Date
7/1/2024
Active Ingredients
DICLOFENAC EPOLAMINEApproval Type
New Drug (NDA)
FDA Application
NDA206976FDA Approved
12/19/2018
On Market Since
9/1/2020
Pharmacological Classes
Price Statistics
The NADAC for LICART 1.3% PATCH has been published 68 times since Jun 21, 2023, and over the history we have for it it has risen 3.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $24.7113 per EA |
|---|---|
| All-time high | $24.7113 (Oct 2, 2024) |
| All-time low | $23.8581 (Jun 21, 2023) |
| Median price | $23.9879 |
| Average price | $24.1579 |
| Largest weekly change | +2.7% (Jun 26, 2024) |
| Weeks tracked | 68 |
| Tracking since | Jun 21, 2023 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
+3.0%
5Y
N/A
All
+3.6%
Last surveyed Oct 2, 2024 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 81% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
IBSA Pharma Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
diclofenac epolamine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Nonsteroidal Anti-inflammatory Drug class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of LICART 1.3% PATCH?
The current National Average Drug Acquisition Cost (NADAC) for LICART 1.3% PATCH, manufactured by IBSA Pharma Inc., is $24.7113 per EA (NDC 71858030505), effective Oct 2, 2024.
How has the price of LICART 1.3% PATCH changed over time?
Over the history we have for it, the NADAC for LICART 1.3% PATCH has risen 3.6%. It has been tracked across 68 weekly CMS publications since Jun 21, 2023.
What are the highest and lowest recorded NADAC prices for LICART 1.3% PATCH?
Since Jun 21, 2023, the NADAC for LICART 1.3% PATCH has ranged from a low of $23.8581 (Jun 21, 2023) to a high of $24.7113 (Oct 2, 2024), with a median of $23.9879 per EA.
Are there cheaper alternatives to LICART 1.3% PATCH?
Yes. 2 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, DICLOFENAC EPOLAMINE 1.3% PTCH, is $4.7071 per EA — about 81% below LICART 1.3% PATCH.
Who manufactures LICART 1.3% PATCH?
LICART 1.3% PATCH (NDC 71858030505) is labeled by IBSA Pharma Inc., and CMS classifies it as a brand product.